The researchers propose a new model for breast cell differentiation that identifies two populations of progenitor cells, one of which appears to be the cell of origin for luminal-like breast cancer, the most common form of the disease. The study, published in the January 19 issue of Cancer Cell, identifies a possible target for breast cancer drugs.
Breast cancers are generally classified in one of two categories. Luminal-like cancers, which are sensitive to hormones, are the most common form of breast cancer and tend to grow more slowly. Basal-like cancers, which are not sensitive to hormones, are more aggressive and tend to have a poorer prognosis. While scientists have predicted that these cancers might arise from different types of progenitor cells, it has been difficult to identify these cells of origin.
A team of researchers led by Charlotte Kuperwasser and Philip Hinds identified different types of breast stem and progenitor cells using a novel mouse model. Previously, researchers had been unable to functionally distinguish between stem cells that make the entire mammary tissue and other progenitor cells due to the shared molecular features of these cell populations.
“It wasn’t clear that breast tissues did in fact contain functionally distinct progenitor cells. Our findings, however, show that luminal-like breast cancer originates from one type of progenitor cell, lobule progenitors, which are the self-renewing cells required to generate the milk-producing structures in breast tissue during pregnancy and lactation. Inhibiting a protein essential to these cells prevented the formation of breast tumors in mice,” said co-senior author Charlotte Kuperwasser, PhD, associate professor in the anatomy and cellular biology department at Tufts University School of Medicine (TUSM) and member of the cell, molecular, and developmental biology and genetics program faculties at Sackler.
The researchers discovered that this population of progenitor cells depends on the activity of a protein called cyclin D1 for self-renewal and differentiation. The team generated a mouse model with inactive cyclin D1 and the gene known to promote luminal-like breast cancer. Compared to controls, the mice lacking in cyclin D1 activity contained very few lobule progenitor cells and had an absence of luminal-like tumors.
“The effects of eliminating cyclin D1 activity were profound. Depriving the lobule progenitor cells of cyclin D1 prevented self-renewal, disrupted normal mammary differentiation, and blocked the formation of luminal-like tumors,” said co-senior author Philip Hinds, PhD, deputy director of the Tufts Medical Center Cancer Center. He is also a professor in the radiation oncology department at TUSM and member of the biochemistry and genetics program faculties at Sackler.
“Now that we have seen that this approach prevents mammary tumor formation, we would like to see if inhibition of cyclin D1 slows or reverses the growth of existing tumors. We predict that targeting cyclin D1 would diminish the progenitor cells that drive luminal-like tumor growth,” continued Hinds.
“If we find that inhibition of cyclin D1 activity combats existing tumors, the protein may serve as a new target for breast cancer drugs,” said Kuperwasser.
Kuperwasser, based at TUSM and Sackler, and Hinds are also both members of the Molecular Oncology Research Institute (MORI) at Tufts Medical Center and the models in development and cancer program at the Tufts Medical Center Cancer Center.
The first authors are Rinath Jeselsohn, MD, a former fellow in hematology/oncology at Tufts Medical Center; and Nelson Brown, MD, PhD, research fellow at MORI and instructor of medicine at Tufts Medical Center. Additional authors are Lisa Arendt, PhD, DVM, senior research associate in the department of anatomy and cellular biology at TUSM; Ina Klebba, senior research assistant in the department of anatomy and cellular biology at TUSM; and Miaofen Hu, MD, PhD, fellow in the Hinds Laboratory at MORI and also an instructor of medicine at Tufts Medical Center.
This study was funded by grants from the National Cancer Institute and the National Center for Research Resources, both parts of the National Institutes of Health; and The Breast Cancer Research Foundation.
Jeselsohn R, Brown NE, Arendt L, Klebba I, Hu MG, Kuperwasser C, Hinds PW. Cancer Cell. 2010 (January 19); 17: 65-76. “Cyclin D1 Kinase Activity Is Required for the Self-Renewal of Mammary Stem and Progenitor Cells that Are Targets of MMTV-ErbB2 Tumorigenesis.” Published online January 19, 2010, doi: 10.1016/j.ccr.2009.11.024
About Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences
Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, biomedical sciences, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. Tufts University School of Medicine and the Sackler School undertake research that is consistently rated among the highest in the nation for its impact on the advancement of medical science.
If you are a member of the media interested in learning more about this topic, or speaking with a faculty member at the Tufts University School of Medicine, the Sackler School of Graduate Biomedical Sciences, or another Tufts health sciences researcher, please contact Siobhan Gallagher at 617-636-6586 or, for this study, Lindsay Peterson at 617-636-2789.